SRZN
Surrozen, Inc./DE
$23.39
+0.09%
$271.6M
No data for this timeframe.
Vol
Market Cap$271.6M
Cap SizeMicro Cap
Analyst ConsensusStrong Buy (91%)
Inst. Holders24 funds
Inst. Value$36.4M
Inst. Activity3 buys / 2 sells
Insider Activity10B / 3S
Insider Net $$2.2M
SEC Reports2
Press Releases1
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·Inc. DE·CIK 0001824893·Prev Close $23.37
Recent Activity
May 13, 2026
Insider
WOODHOUSE DAVID J was granted 5,550 shares
Director
May 13, 2026
Insider
Berkenblit Anna was granted 5,550 shares
Director
May 13, 2026
Insider
BJERKHOLT ERIC was granted 5,550 shares
Director
May 12, 2026
other
Surrozen to Present at Upcoming Healthcare Investor Conference
Surrozen to Present at Upcoming Healthcare Investor Conference
May 5, 2026
SEC
CEO Parker Craig and COO Charles Williams sold a combined $219K worth of SRZN shares at ~$33.33 per share. The total val
CLUSTER — Impact 2/10
Mar 23, 2026
SEC
Surrozen, Inc. has filed an S-3 shelf registration statement with the SEC, authorizing the potential issuance of up to $
S-3 — Impact 7/10
Inst.
AMERIPRISE FINANCIAL INC — DOUBLED
159,711 shares ($4.7M)
Inst.
FRED ALGER MANAGEMENT, LLC — TRIM
71,697 shares ($2.1M)
Price Targets
$42.50
+81.7% upside
Strong Buy
Current $23.39
Low $40.00
Median $43.00
High $44.00
4 analysts
$40.00
$44.00
Analyst Ratings
3Strong Buy
7Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 7, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| Apr 21, 2026 | TD Cowen | INITIATE | Buy |
| Mar 24, 2026 | Cantor Fitzgerald | REITERATE | Overweight → Overweight |
| Mar 24, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Feb 19, 2026 | Cantor Fitzgerald | INITIATE | Overweight |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-1.26 ▼ -13.5% | $-1.28 — $-1.24 | -11% YoY | 2 |
| Next Q | $-1.29 ▼ -13.1% | $-1.40 — $-1.19 | 64% YoY | 2 |
| Current FY | $-3.70 | $-3.70 — $-3.70 | 1 | |
| Next FY | $-3.98 ▼ -11.8% | $-4.46 — $-3.51 | -8% YoY | 2 |
Latest Reports
NEUTRAL
CLUSTER
2/10
CEO Parker Craig and COO Charles Williams sold a combined $219K worth of SRZN shares at ~$33.33 per share. The total val
May 5, 2026
BEARISH
S-3
7/10
Surrozen, Inc. has filed an S-3 shelf registration statement with the SEC, authorizing the potential issuance of up to $
Mar 23, 2026
MIXED
Press
6/10
Surrozen reported its 2025 financial results, showing a significant increase in net loss to $242.0 million due to non-ca
Mar 23, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| Woodline Partners LP | $6.6M | DOUBLED |
| BALYASNY ASSET MANAGEMENT L.P. | $5.9M | DOUBLED |
| VANGUARD CAPITAL MANAGEMENT LLC | $4.9M | — |
| AMERIPRISE FINANCIAL INC | $4.7M | DOUBLED |
| ADAGE CAPITAL PARTNERS GP, | $2.6M | ADD |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 13, 2026 | WOODHOUSE DAVID | A | $0.00 |
| May 13, 2026 | Berkenblit Anna | A | $0.00 |
| May 13, 2026 | BJERKHOLT ERIC | A | $0.00 |
| May 13, 2026 | CHAI CHRISTOPHER | A | $0.00 |
| May 13, 2026 | Haak-Frendscho Mary | A | $0.00 |
24 institutional holders with $36.4M total value (1,284,540 shares) as of 2026-Q1. Top holders: Woodline, BALYASNY, VANGUARD. Net buying activity: 3 institutions added/increased vs 2 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | Woodline Partners LP | 227,848 | $6.6M | 18.2% | DOUBLED +378.4% |
| 2 | BALYASNY ASSET MANAGEMENT L.P. | 203,888 | $5.9M | 16.3% | DOUBLED +169.3% |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 169,092 | $4.9M | 13.5% | — |
| 4 | AMERIPRISE FINANCIAL INC | 159,711 | $4.7M | 12.8% | DOUBLED +143.1% |
| 5 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 88,653 | $2.6M | 7.1% | ADD +37.1% |
| 6 | FRED ALGER MANAGEMENT, LLC | 71,697 | $2.1M | 5.7% | TRIM -28.0% |
| 7 | RENAISSANCE TECHNOLOGIES LLC | 49,126 | $1.4M | 3.9% | DOUBLED +117.1% |
| 8 | TWO SIGMA INVESTMENTS, LP | 39,482 | $1.2M | 3.2% | — |
| 9 | CITADEL ADVISORS LLC | 35,469 | $1.0M | 2.8% | ADD +32.8% |
| 10 | VANGUARD FIDUCIARY TRUST CO | 35,390 | $1.0M | 2.8% | — |
| 11 | BlackRock, Inc. | 27,851 | $811.3K | 2.2% | ADD +90.0% |
| 12 | STATE STREET CORP | 27,726 | $807.7K | 2.2% | ADD +82.5% |
| 13 | GOLDMAN SACHS GROUP INC | 25,851 | $753.0K | 2.1% | — |
| 14 | LMR Partners LLP | 23,557 | $686.2K | 1.9% | — |
| 15 | MORGAN STANLEY | 22,446 | $653.9K | 1.8% | TRIM -39.3% |
| 16 | MARSHALL WACE, LLP | 18,930 | $551.4K | 1.5% | ADD +73.1% |
| 17 | Alyeska Investment Group, L.P. | 10,188 | $296.8K | 0.8% | TRIM -50.0% |
| 18 | Hudson Bay Capital Management LP | 8,653 | $252.1K | 0.7% | — |
| 19 | Vanguard Global Advisers, LLC | 2,570 | $74.9K | 0.2% | — |
| 20 | BARCLAYS PLC | 1,888 | $55.0K | 0.2% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| AMERIPRISE FINANCIAL INC | DOUBLED | 65,688 | 159,711 | +143.1% | $4.7M | 2026-Q1 |
| FRED ALGER MANAGEMENT, LLC | TRIM | 99,560 | 71,697 | -28.0% | $2.1M | 2026-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 22,626 | 49,126 | +117.1% | $1.4M | 2026-Q1 |
| MORGAN STANLEY | TRIM | 36,961 | 22,446 | -39.3% | $653.9K | 2026-Q1 |
| MARSHALL WACE, LLP | ADD | 10,939 | 18,930 | +73.1% | $551.4K | 2026-Q1 |
| Woodline Partners LP | DOUBLED | 48,193 | 230,572 | +378.4% | $5.2M | 2025-Q4 |
| BALYASNY ASSET MANAGEMENT L.P. | DOUBLED | 70,732 | 190,489 | +169.3% | $4.3M | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 6 | 29,608 | +493366.7% | $669.1K | 2025-Q4 |
| BlackRock, Inc. | ADD | 13,743 | 26,118 | +90.0% | $590.3K | 2025-Q4 |
| STATE STREET CORP | ADD | 13,326 | 24,326 | +82.5% | $549.8K | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 14,726 | 22,626 | +53.6% | $511.3K | 2025-Q4 |
| CITADEL ADVISORS LLC | ADD | 10,451 | 13,875 | +32.8% | $178.8K | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | NEAR_EXIT | 52 | 6 | -88.5% | $77.00 | 2025-Q3 |
| VANGUARD GROUP INC | DOUBLED | 68,026 | 218,950 | +221.9% | $2.0M | 2025-Q2 |
| DRIEHAUS CAPITAL MANAGEMENT LLC | TRIM | 204,934 | 67,566 | -67.0% | $604.0K | 2025-Q2 |
| UBS Group AG | ADD | 197 | 259 | +31.5% | $2.3K | 2025-Q2 |
| RA CAPITAL MANAGEMENT, L.P. | DOUBLED | 282,580 | 679,130 | +140.3% | $7.9M | 2025-Q1 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | ADD | 64,653 | 88,653 | +37.1% | $1.0M | 2025-Q1 |
| UBS Group AG | DOUBLED | 32 | 197 | +515.6% | $2.3K | 2025-Q1 |
| Alyeska Investment Group, L.P. | TRIM | 20,376 | 10,188 | -50.0% | $146.2K | 2024-Q4 |
11 unique insiders with 24 transactions. Net insider value: $2.2M ($2.4M bought, $271.5K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 13, 2026 | WOODHOUSE DAVID J | Director | AWARD | 5,550 | — | — |
| May 13, 2026 | Berkenblit Anna | Director | AWARD | 5,550 | — | — |
| May 13, 2026 | BJERKHOLT ERIC | Director | AWARD | 5,550 | — | — |
| May 13, 2026 | CHAI CHRISTOPHER Y | Director | AWARD | 5,550 | — | — |
| May 13, 2026 | Haak-Frendscho Mary | Director | AWARD | 5,550 | — | — |
| May 13, 2026 | Rothenberg Mace | Director | AWARD | 5,550 | — | — |
| May 13, 2026 | Kutzkey Tim | Director | AWARD | 5,550 | — | — |
| May 4, 2026 | Parker Craig C | Chief Executive Officer | SELL | 4,524 | $33.33 | $150.8K |
| May 4, 2026 | Williams Charles O | Chief Operating Officer | SELL | 2,036 | $33.33 | $67.9K |
| May 4, 2026 | Li Yang | Exec. Vice President, Research | SELL | 1,584 | $33.33 | $52.8K |
| May 1, 2026 | Parker Craig C | Chief Executive Officer | EXERCISE | 12,500 | — | — |
| May 1, 2026 | Williams Charles O | Chief Operating Officer | EXERCISE | 5,625 | — | — |
| May 1, 2026 | Li Yang | Exec. Vice President, Research | EXERCISE | 4,375 | — | — |
| Mar 31, 2026 | Li Yang | Exec. Vice President, Research | GIFT | 1,666 | — | — |
| Mar 24, 2026 | TCG Crossover GP II, LLC | 10%+ Owner | BUY | 53,329 | $24.69 | $1.3M |
| Mar 23, 2026 | TCG Crossover GP II, LLC | 10%+ Owner | BUY | 7,612 | $24.90 | $189.5K |
| Mar 16, 2026 | TCG Crossover GP II, LLC | 10%+ Owner | BUY | 595 | $24.99 | $14.9K |
| Mar 13, 2026 | TCG Crossover GP II, LLC | 10%+ Owner | BUY | 17,717 | $24.88 | $440.7K |
| Mar 12, 2026 | TCG Crossover GP II, LLC | 10%+ Owner | BUY | 6,187 | $24.99 | $154.6K |
| Feb 12, 2026 | TCG Crossover GP II, LLC | 10%+ Owner | BUY | 547 | $23.86 | $13.1K |
| Feb 11, 2026 | TCG Crossover GP II, LLC | 10%+ Owner | BUY | 8,882 | $23.58 | $209.4K |
| Feb 3, 2026 | TCG Crossover GP II, LLC | 10%+ Owner | BUY | 2,178 | $21.94 | $47.8K |
| Feb 2, 2026 | TCG Crossover GP II, LLC | 10%+ Owner | BUY | 366 | $21.38 | $7.8K |
| Jan 30, 2026 | TCG Crossover GP II, LLC | 10%+ Owner | BUY | 2,136 | $21.39 | $45.7K |
2 SEC filing reports analyzed. Sentiment: 0 bullish, 1 bearish, 0 mixed, 1 neutral. Avg impact: 4.5/10.
Current analyst consensus: Strong Buy (91% buy). Based on 11 analysts: 3 strong buy, 7 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$42.50 mean target
+81.7% upside
Strong Buy (3.00)
$40.00 Low
$44.00 High
| Metric | Value |
|---|---|
| Current Price | $23.39 |
| Target Low | $40.00 |
| Target Mean | $42.50 |
| Target Median | $43.00 |
| Target High | $44.00 |
| # Analysts | 4 |
| Recommendation | Strong Buy (3.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-1.26 | $-1.28 | $-1.24 | -10.8% | -13.5% | 0↑ 2↓ | $0.0B | -11.6% | 2 |
| Next Q 2026-09-30 |
$-1.29 | $-1.40 | $-1.19 | 64.1% | -13.1% | 0↑ 2↓ | $0.0B | -11.6% | 2 |
| Current FY 2026-12-31 |
$-3.70 | $-3.70 | $-3.70 | — | +0.0% | — | $0.0B | 68.8% | 1 |
| Next FY 2027-12-31 |
$-3.98 | $-4.46 | $-3.51 | -7.7% | -11.8% | 0↑ 2↓ | $0.0B | -40.8% | 2 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-1.260 | |
| 7d ago | $-1.110 | -0.150 |
| 30d ago | $-1.110 | -0.150 |
| 60d ago | $-1.360 | +0.100 |
| 90d ago | $-1.170 | -0.090 |
3 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 2 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 7, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Apr 21, 2026 | TD Cowen | INITIATE | — | Buy |
| Mar 24, 2026 | Cantor Fitzgerald | REITERATE | Overweight | Overweight |
| Mar 24, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Feb 19, 2026 | Cantor Fitzgerald | INITIATE | — | Overweight |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 3 | 7 | 1 | 0 | 0 | 91% | |
| May 1, 2026 | 3 | 7 | 1 | 0 | 0 | 91% | |
| Apr 1, 2026 | 3 | 6 | 1 | 0 | 0 | 90% | |
| Mar 1, 2026 | 3 | 5 | 1 | 0 | 0 | 89% | |
| Feb 1, 2026 | 3 | 4 | 1 | 0 | 0 | 88% | |
| Jan 1, 2026 | 3 | 4 | 1 | 0 | 0 | 88% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 12, 2026
other
Surrozen to Present at Upcoming Healthcare Investor Conference
Surrozen to Present at Upcoming Healthcare Investor Conference
May 8, 2026
earnings_calendar
SRZN Q1 2026 Earnings Scheduled — 2026-05-08
Mar 30, 2026
earnings_calendar
SRZN Q4 2025 Earnings After Market Close — 2026-03-30
Mar 23, 2026
earnings
Surrozen Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Surrozen Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update